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Abstract
Background: Increased expression of toll-like receptor 4 (TLR4) and its endogenous ligands, is characteristic of
rheumatoid arthritis (RA) synovitis. In this study, we evaluated how these TLR4 ligands may drive pathogenic
processes and whether the fine profiling of anti-citrullinated protein antibodies (ACPA) based on their target
specificity might provide a simple means to predict therapeutic benefit when neutralizing TLR4 in this disease.
Methods: The capacity of RA synovial fluids (RASF) to stimulate cytokine production in monocytes from patients
with RA was analyzed by ELISA. The presence of TLR4 activators in RASF was determined by measuring the levels
of ACPA, ACPA subtypes with reactivity to specific citrullinated peptides and other TLR4 ligands. Neutralization of
TLR4 signaling was investigated using NI-0101, a therapeutic antibody that targets TLR4.
Results: RASF exhibited a heterogeneous capacity to induce production of proinflammatory cytokines by monocytes
isolated from patients with RA. Such cytokine responses were significantly modified by TLR4 blockade achieved using
NI-0101. The analysis of the content of RASF and matched sera demonstrated that ACPA fine specificities in patient
samples predict cellular response to anti-TLR4 exposure in vitro.
Conclusion: TLR4 represents a possible therapeutic target in RA. Our study demonstrates that TLR4 inhibition in an
ex vivo model of RA pathogenesis can significantly modulate cytokine release and does so in specific subgroups of
RA patient-derived samples. It also suggests that ACPA fine profiling has the potential to identify RA patients with a
predominantly TLR4-driven pathotype that could be used to predict preferential response to TLR4 antagonism.
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Background
Synovial inflammation is a hallmark of RA. While proin-
flammatory cytokines are considered to have a pivotal
role in the pathogenesis of RA [1], the factors respon-
sible for the initiation and perpetuation of the complex
cytokine response are still not completely understood.
Toll-like receptors (TLRs) play an important role in the
initiation of innate immune responses and in the in-
struction of the adaptive arms of immunity. Both
components of immune effector function are evident in
RA pathogenesis and coincide with the tissue lesion. In
particular, by their capacity to recognize the endogenous
ligands released during tissue damage TLRs are attractive
candidates for the mediation of chronicity in RA [2–6].
TLR4 is a receptor for immune complexes containing
citrullinated proteins, in particular citrullinated fibrino-
gen (cFb-IC). Anti-cFb antibodies are present in over
50 % of patients with RA [7, 8]. Furthermore, anti-
citrullinated protein antibodies (ACPA) titers correspond
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with more aggressive RA progression [9]. The presence
of ACPA is one of the classification criteria for RA. For
these reasons, the potential role of a subgroup of ACPA/
cit-peptide complexes with reactivity to TLR4 deserves
to be investigated as a potential pathogenic pathway in
RA. TLR4 deficiency or TLR4 pharmacological inhibition
reduces disease progression in mouse models of RA
[10, 11]. TLR4 is expressed both on macrophages and
synovial fibroblasts in synovial membrane in RA, two
key cell types implicated in cytokine production within
the inflamed joint [12, 13]. Recently, it has been reported
that myeloid cells from patients with RA demonstrate an
exaggerated response to TLR4 agonism [14, 15].
The inflammation present in the joints, the primary site
of inflammation in patient with RA, has been reported to
be heterogeneous among individual patients at the cellular
and molecular levels [16]. Thus, to further investigate the
role of TLR4 and its endogenous ligands in RA pathogen-
esis, we evaluated levels of different TLR4 ligands in RA
synovial fluid (RASF), including antibodies against citrulli-
nated proteins and their potential association with TLR4-
dependent inflammation. We examined the cytokine in-
duction capacity of RASF with an in vitro bioassay that
evaluated the production of cytokines by monocytes from
patients with RA. The contribution of TLR4 activation to
RASF-stimulated cytokine production was assessed in the
presence of NI-0101, an anti-human TLR4 monoclonal
antibody (mAb) [17]. We found correlation between
TLR4-dependent cytokine induction and ACPA targeting
specific citrullinated epitopes in synovial fluid (SF) and in
serum from patients with RA.
Methods
Patients, RASF and paired sera samples
RASF samples from the inflamed joints of 40 patients
with RA were obtained from the ethically approved
Tissue Bank of the Universities of Glasgow and Geneva.
RA was diagnosed according to the 1987 revised cri-
teria of the American College of Rheumatology (ACR).
At the time of fluid collection, the mean age of patients
with RA was 62 years (range 46–77 years). Paired RA
sera samples were collected from 22 of these patients:
post-mortem SF samples from 4 subjects without RA
(purchased from Asterand) were used as controls.
RA monocyte preparation
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized whole blood obtained from patients with
RA (n = 7) by Ficoll Paque (GE Healthcare) density gra-
dient centrifugation. Isolated cells were suspended in
complete medium containing RPMI medium supple-
mented with 10 % heat-inactivated fetal bovine serum,
2 mM L-glutamine, 50 U/mL penicillin, and 50 μg/mL
streptomycin (Sigma). CD14+ monocytes were then
separated from PBMCs using anti-CD14 mAb-coupled
magnetic beads followed by MACS column separation
according to the manufacturer’s protocol (Miltenyi Bio-
tec). Flow cytometric analysis revealed that CD14+
monocyte cell fractions contained >85 % CD11b+ cells.
Cell stimulation
Monocytes derived from patients with RA were plated
in 96-well culture plates at 5.104 cells/well. NI-0101,
formerly designated as Hu 15C1 [17], or a human IgG1
isotype control (clone DA4) was added to wells at a final
concentration of 20 μg/mL. Plates were incubated
(30 minutes, 37 °C) prior to adding SF (pooled or indi-
vidual) diluted to a final concentration of 2.5 %. Ultrapure
lipopolysaccharide (LPS) (Salmonella minnesota), added
at 10 ng/mL (List Biological Laboratories), was used as a
positive control. After incubation (24 h, 37 °C), superna-
tants were harvested and cytokine levels measured by
ELISA (eBiosciences) or multiplexing assays (Invitrogen).
TLR4 ligand quantification and ACPA fine specificity assays
RASF were characterized for levels of ACPA (commercial
anti-cyclic citrullinated peptide (CCP)-2 ELISA, Eurodiag-
nostica), HMGB1, and S100A8/A9 using commercial
ELISA kits (Diagnostik Service GmbH, Hycult and IBL
International, respectively) according to the manufac-
turers’ protocols. Antibody reactivity against the citrulli-
nated form of linear peptides derived from fibrinogen and
histone 2A were determined by ELISA. Sequences of
citrullinated peptides used in the assay are presented in
Additional file 1. Ninety six well plates (Nunc) were
coated and incubated overnight with peptides in their
native or citrullinated form, all at a concentration of
10 μg/mL. Plates were washed and blocked (1 h, 4 °C) with
2 % BSA in PBS. For the detection of specific IgG, RASF
samples diluted 1:50 in 2 % BSA, 2 M NaCl in PBS were
added and incubated (1 h, 4 °C). Plates were then washed
prior to adding an anti-human IgG Fc-horseradish perox-
idase (HRP) (Sigma; 1 h). Tetramethylbenzidine (Sigma)
was added and the reaction stopped with 2 N H2SO4.
Plates were read at 450 nm using an ELISA plate
reader (BioTek Instruments). The difference (delta) in
optical density (OD) was calculated as the immunoreactiv-
ity against citrulline peptide minus the immunoreactivity
against arginine control peptide. The data are shown as
arbitrary units where the delta OD for each RASF sample
was normalized by the threshold calculated with non-RA
SF samples (set at 1, dashed line) above which a sample is
considered positive.
RA patient stratification
RASF samples from patients with RA were classified as
NI-0101 responders (R) if NI-0101 was able to block
(partially or totally) RASF-induced IL-6 production from
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RA monocytes. Others were classified as NI-0101 non-
responders (NR). Correlation was tested between NI-
0101 responder or non-responder samples from patients
with RA and the presence of ACPA, specific ACPA fine
profiles, and levels of TLR4 ligands (see Additional file
2). Endotoxin levels were lower than 1.22 EU/mL in the
final concentration of the RASF samples measured using
the Limulus amebocyte lysate (LAL) test. This level of
endotoxin did not stimulate TLR4 activation of myeloid
cells in an LPS dose response study (data not shown).
Statistical analysis
The Mann-Whitney U test was used to compare differ-
ence between groups. Statistical significance is denoted
as follows: ***p < 0.001, **p < 0.01, *p < 0.05.
Results
Synovial fluids from patients with RA contain activators
that stimulate disease-relevant cell types through the
TLR4 pathway
As RASF from some patients with RA contain endogen-
ous TLR4 ligands, and as joint-infiltrating myeloid cells
are a source of proinflammatory cytokines in RA, we
first investigated whether the endogenous TLR4 ligands
in RASF samples contribute to the inflammatory poten-
tial of RASF, by stimulating myeloid cells from RA do-
nors. The limited volume of individual RASF samples
used in this study was not sufficient to be tested with
multiple RA monocyte donors for the stimulation of
multiple cytokines. A pool of RASF samples was thus
created using eight ACPA-positive RASF samples con-
taining high levels of TLR4 ligands (see Additional file 3)
to allow investigation of the broad inflammatory poten-
tial of TLR4 ligands in RASF samples with multiple RA
myeloid cell donors. RASF samples with high levels of
ACPA are expected to contain ACPA immune com-
plexes, which have been reported as TLR4 ligands. The
involvement of TLR4 signaling was assessed with a
monoclonal antibody, NI-0101, which has been devel-
oped to bind human TLR4 and neutralize its activation.
To test NI-0101 specificity for TLR4 versus other TLRs,
a monocytic TLR reporter cell line was used in combin-
ation with the ligands for various TLRs.
NI-0101 blocked TLR4-induced activation but had no
effect on other TLRs (see Additional file 4). Incubation
with either LPS or the pooled RASF containing high
levels of endogenous TLR4 ligands, in contrast to non-
RA SF (pooled from four subjects without RA), stimu-
lated a significant increase in IL-6 release from RA-
derived monocytes from seven individual RA donors
(see Additional file 5) (data not shown). Blocking TLR4
activation using NI-0101 impaired the increase in cyto-
kine production, often bringing cytokine levels back to
baseline (see Additional file 5). The capacity of RASF
containing high levels of endogenous TLR4 ligands to
induce IL-6 production and its blockade by NI-0101
was also observed using RA synovial fibroblasts (see
Additional file 6). In addition, RASF-induced cytokine
production was shown to be TNF-independent, as etaner-
cept, a soluble TNF receptor (TNFR)-Fc fusion protein,
had no impact on RASF-stimulated IL-6 production (see
Additional file 6). The pooled RASF samples containing
high levels of endogenous TLR4 ligands also induced sig-
nificant production of TNFα, IL-1β and IL-8 (Fig. 1) by
monocytes derived from patients with RA. Furthermore,
the production of each cytokine was significantly reduced
when TLR4 signaling was neutralized using NI-0101.
These data suggest that RASF containing activators of the
TLR4 pathway can play a role in stimulating immune and
non-immune cells within inflamed joints.
As the pool of eight RASF samples containing high
levels of endogenous TLR4 ligands provoked a potent in-
flammatory response, we next sought to investigate the
ability of individual RASF samples containing different
levels of endogenous TLR4 ligands to induce cytokine
production and explore variability among patient do-
nors. Using monocytes isolated from patients with RA,
we observed that 29 out of 40 tested RASF samples
stimulated IL-6 production, which was inhibited by the
presence of NI-0101 in 20 of those 29 samples (Fig. 2a
and b and Additional file 7). The RASF samples that did
not stimulate IL-6 production and those that stimulated
IL-6 production but did not respond to NI-0101 treat-
ment were designated as NI-0101 non-responders (Fig. 2a).
The RASF samples that stimulated IL-6 production and
demonstrated responsiveness (partial or total) to NI-0101
treatment were designated as NI-0101 responders (Fig. 2b).
In contrast to the lack of effect of NI-0101 on RASF-
stimulated IL-6 production in the NI-0101 non-responder
group (Fig. 2c), treatment with NI-0101 reduced RASF-
induced IL-6 by a mean value of 61 % in NI-0101 re-
sponder samples (Fig. 2d). These results suggest that indi-
vidual RASF can cause variable levels of TLR4-dependent
cytokine production by monocytes from patients with RA.
Expression of ACPA and TLR4 ligands in RASF samples and
their correlation with TLR4 blockade of cytokine release
We next analyzed the presence of ACPA and several
known TLR4 agonists including HMGB1 and S100A8/
A9 in individual RASF samples. In contrast to non-RA
SF samples, increased levels of ACPA and TLR4 ligands
were detected in samples from patients with RA (Fig. 3a).
Using 25 U/mL as the cutoff (the cutoff used in clinical
practice), samples were divided into an ACPA-positive
(n = 22) and an ACPA-negative (n = 18) subset. A con-
tinuous distribution was observed for the expression of
S100A8/A9 and HMGB1 (Fig. 3a). To correlate the
degree of cytokine inhibition by NI-0101 in individual
Hatterer et al. Arthritis Research & Therapy  (2016) 18:224 Page 3 of 12
RASF-induced cytokine production assays, with ACPA
and TLR4 ligand levels in RASF, a sample was designated
as non-responder or responder to NI-0101 blockade based
on the ability of NI-0101 to decrease RASF-induced IL-6
production from RA monocytes (Fig. 2). Additional file 2
depicts the stratification of patients with RA from initial
assessment of NI-0101 response to biomarker investi-
gation. On average, ACPA and HMGB1 in the NI-0101
responder group were significantly higher than those
in the NI-0101 non-responder group, whereas S100A8/
A9 was similar between the two groups (Fig. 3b and
Additional file 8).
Autoantibodies against specific citrullinated peptides are
associated with NI-0101 response
Interestingly, there was association with inhibition by
NI-0101 in 17 out of 22 ACPA-positive RASF samples,
but not in the remaining 5 samples. As ACPA from an
individual patient comprise a mixture of antibodies rec-
ognizing different citrullinated proteins, e.g., fibrinogen,
histone 2A and fibronectin [18], we hypothesized that
the citrullinated proteins characterizing ACPA in a given
patient in the NI-0101-sensitive group may be different
from those in the non-responder group. Therefore,
ACPA-positive RASF samples were further classified
according to reactivity to individual citrullinated pep-
tides from different proteins. Samples positive for
reactivity to citrullinated peptides derived from the α-
chains and β-chains of fibrinogen (cFbα-pept and cFbβ-
pept) and histone 2A (cH2A-pept) were represented
significantly more often in the NI-0101 responder
group than in the non-responder group (Fig. 4a). To
determine the relative predictive power of different
citrullinated peptides to identify NI-0101 responders,
we assessed the sensitivity and specificity of individual
peptides and different combinations of the peptides
(Table 1). cFbα peptide was the strongest predictor
among the individual peptides, with sensitivity of 94 %
and specificity of 80 %. Combining anti-cFbα-derived
and anti-cH2A-derived peptides increased the sensitiv-
ity to 100 % with specificity of 80 % (Table 1). Adding
to the combination the reactivity to cFbβ did not fur-
ther improve the predictive power.
We next assessed the capacity of the citrullinated pep-
tides to predict responders to NI-0101 independently of
ACPA positivity. Similar to the ACPA-positive samples,
when both ACPA-positive and ACPA-negative RASF
samples were included, all samples positive for reactivity
to cFbβ peptide and the majority of samples positive for
reactivity to cFbα or cH2A peptides were in the NI-0101
Fig. 1 Interference in toll-like receptor 4 (TLR4) signaling blocks IL-6, TNFα, IL-1β and IL-8 production by monocytes stimulated by synovial fluid
from patients with rheumatoid arthritis (RASF). TLR4 signaling was blocked with anti-human TLR4 monoclonal antibody, NI-0101. Representative
data shown for monocytes obtained from one of seven patients with rheumatoid arthritis (RA). Data are presented as mean +/- SEM. The Mann-
Whitney U test was performed to identify differences among groups: **p < 0.01, ***p < 0.001
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responder group (Fig. 4b). cFbα peptide was the stron-
gest predictor among the individual peptides, with sensi-
tivity of 85 % and specificity of 95 %. In comparison,
ACPA positivity predicted NI-0101 responders with sen-
sitivity of 85 % and specificity of 75 %. Similar to the
APCA-positive samples, combining the results of the
anti-cFbα-derived and anti-cH2A-derived peptides pro-
vided the highest sensitivity and specificity to predict
NI-0101 response with sensitivity of 90 % and specificity
of 95 % (Table 1).
In order to further characterize these potential pre-
dictive biomarkers of patients’ responses to NI-0101,
we performed receiver operating characteristic (ROC)
analysis. Additional file 9 shows detailed sensitivity and
specificity data with the 95 % confidence interval, for
the three citrullinated peptides. The area under the
ROC curve was 0.83 for CCP2 and 0.93, 0.86 and 0.95
for cFbα-pept, cH2A-pept and the combination of both
peptides, respectively. These results demonstrated that
reactivity to a specific set of citrullinated peptides pre-
dicted the response to NI-0101 better than ACPA posi-
tivity alone (based on the anti-CCP2 test).
ACPA fine profiling in serum samples from patients with
RA and its correlation with the capacity for in vitro
inhibition by NI-0101 in their paired RASF
Paired RA serum and RASF samples were obtained from
22 patients with RA. ACPA positivity in RASF correlated
with positivity in the paired serum samples (Fig. 5a),
suggesting that ACPA profiles in serum reflect those in
the joint. ACPA positivity in the sera was associated with
a clear inhibition of cytokine production by NI-0101 in
matched RASF samples. Interestingly 8 out of the 13
ACPA-positive paired RA serum samples were associ-
ated with NI-0101 response, whereas 5 were not (Fig. 5b).
Therefore, ACPA-positive paired RA serum samples
were further classified according to reactivity to individual
citrullinated peptides from different proteins. Samples
positive for reactivity to cFbα-pept were significantly more
frequent in the NI-0101 responder group than in the non-
responder group (Fig. 5c). A trend for presence of cFbβ-
derived and cH2A-derived peptides was observed (Fig. 5c).
We next assessed the capacity of specific citrullinated
peptides to predict NI-0101 responders independently
of ACPA positivity. The majority of samples positive
A B
C D
Fig. 2 Heterogeneous capacity of rheumatoid arthritis (RA) synovial fluid (RASF) samples to stimulate cytokine production and respond to TLR4
blockade. RASF samples from patients (Pat) were classified as NI-0101 responders if NI-0101 was able to block (partially or totally) RASF-induced
IL-6 production from RA monocytes. Others were classified as NI-0101 non-responders. a, b Representative examples of RASF from non-responders
(Pat#13, Pat#35) and from responders (Pat#27, Pat#18). Of the 40 RASF samples tested, 20 were classified as NI-0101 responders (50 %) and 20 as
NI-0101 non-responders (50 %). c, d Mean levels of IL-6 in RASF NI-0101 responder and non-responder RASF samples. IL-6 is presented as normalized
values with IL-6 levels induced by RASF arbitrarily set as 100 % induction. RASF samples that were unable to induce IL-6 from RA monocytes but
were impacted upon by NI-0101 are excluded from the non-responder group. The Mann-Whitney U test was performed to test for differences
among groups; ***p < 0.001, *p < 0.05
Hatterer et al. Arthritis Research & Therapy  (2016) 18:224 Page 5 of 12
for reactivity to cFbα, cFbβ or cH2A peptides were
significantly associated with the NI-0101 responder
group (Fig. 5d).
Discussion
Genetics, environmental risk factors, autoantibody pat-
terns and cytokine profiles described in RA are commen-
surate with the well-recognized clinical heterogeneity of
this disease. Unfortunately, there is no biomarker available
to predict the response of an individual patient with RA to
current therapies. This has an impact on quality of care
and increases the financial burden. It may also expose
patients to drug-related risk with no tangible benefit.
Thus, the identification of therapeutic agents targeting
new pathogenic pathways and identifying biomarkers to
predict patient response to these agents may respond to
the unmet needs in RA.
In the present study, we demonstrated that RASF-
stimulated cytokine production in a subgroup of patients
with RA was mediated through TLR4 activation. In
particular, ACPA antibodies reactive to a set of specific
citrullinated peptides and several TLR4 ligands were
expressed heterogeneously in the RASF samples and
their positivity and levels were correlated with the ability
of the RASF samples to stimulate inflammatory cytokine
production. We further demonstrated that ACPA fine
profiles in sera predict RASF-stimulated TLR4 activation.
These data demonstrate the possible pathogenic role of
TLR4 activation in a subgroup of patients with RA and
that the relative levels of its ligands may represent poten-
tial biomarkers to predict patient responses to NI-0101.
RA is a heterogeneous autoimmune disease with the
different pathways involved leading to joint inflammation.
Synovial fluid represents the complex microenvironment
in the synovium. In particular, several TLR4 ligands may
contribute to RASF-induced cytokine production, as many
TLR4 activators have been described in synovial tissues
[1, 5, 19–21]. Several TLRs, including TLR2 and TLR4,
have been suggested to play a role in joint inflammation.
The idea of the involvement of TLR2 in RA is supported
A
B
Fig. 3 Expression of anti-citrullinated protein antibodies (ACPA) and ligands of toll-like receptor 4 in samples of synovial fluid (SF) from patients
with rheumatoid arthritis (RA) and correlation between these and NI-0101 response. a Expression of ACPA, HMGB1 and S100A8/A9 in SF
from subjects without RA (non-RA SF) (n = 4 samples) and patients with RA (RASF) (n = 40 samples). b Correlation between ACPA, HMGB1 or
S100A8/A9 and NI-0101 response. RASF samples were classified as NI-0101 non-responders (NR) or NI-0101 responders (R) according to Fig. 2.
The Mann-Whitney U test was performed to test for differences among groups; *p < 0.05, **p < 0.01
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by enhanced expression of TLR2 in synovial lining cells
[22–26] and elevated levels of TLR2 ligands in synovial
tissues in RA [27, 28, 29–31]. In addition, an anti-TLR2
antibody has recently been demonstrated to decrease
inflammation in a mouse model of arthritis [32], and
blockade of TLR2 to reduce spontaneous cytokine release
from synovial explant cultures in RA [33].
Interestingly, our data demonstrated that RASF-
stimulated cytokine production in RA monocytes was
almost totally reversed by NI-0101 exposure in some
HMGB1-positive samples. These results suggest that
TLR4 may be required for the endogenous ligands in
RASF to induce proinflammatory cytokine production
and that TLR4 blockade alone can prevent the cytokine
production. Consistent with this observation, we dem-
onstrated that interfering with TLR4 signaling alone is
sufficient to block synergistic IL-6 induction from
monocytes stimulated by the combined TLR2 and
TLR4 activation (see Additional file 10). Our data point
to a pathogenic role for multiple TLR4 ligands in joint
inflammation in a subgroup of patients with RA, and
demonstrate that NI-0101 can effectively block these
pathogenic ligands. Because of the multiplicity of TLR4
ligands in RA, direct blockade of the receptor activation
independent of ligands likely affords a more promising
strategy than inhibiting a single ligand of TLR4. In this
A
B
Fig. 4 Anti-citrullinated protein antibodies (ACPA) fine specificity in the synovial fluid samples of patients with rheumatoid arthritis and their
correlation with NI-0101 response. Antibody reactivity against the citrullinated peptides derived from fibrinogen-α (cFbα − pept), fibrinogen-β
(cFbβ-pept) and histone-2A (cH2A-pept) were determined by ELISA and expression in synovial fluids was measured in ACPA-positive rheumatoid
arthritis synovial fluid (RASF) samples (a) (n = 22) and both ACPA-negative and ACPA-positive RASF samples (b) (n = 40). RASF samples were
classified as NI-0101 non-responders (NR) or NI-0101 responders (R). The Mann-Whitney U test was performed to compare observed changes;
***p < 0.001, **p < 0.01, *p < 0.05
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aspect, NI-0101 has been demonstrated to be a ligand-
independent TLR4 blocker and thus, well-positioned to
block TLR4 activation in the subgroup of patients with
increased expression of TLR4 ligands [17].
Among the different types of autoantibodies, ACPA
are highly specific to RA and are reported as being
pathogenic and associated with the most severe and
erosive forms of the disease [34–37]. The mechanism
by which ACPA promote inflammation is proposed to
be related to ACPA activating complement, abnormal
glycosylation pattern or IC formed by ACPA and citrul-
linated proteins, resulting in a higher affinity for Fc
gamma receptors (FcγRs) [7, 38–42]. Interestingly, in
the present study, we observed that TLR4-dependent
cytokine induction was more frequent in ACPA-
positive compared to ACPA-negative samples, suggest-
ing that the level of ACPA may dictate the response of
individual patients with RA to TLR4 blockade.
Our data also demonstrated that ACPA reactivity to
citrullinated Fbα-derived, Fbβ-derived and H2A-derived
peptides is associated with NI-0101 response. Further-
more, combining positivity for anti-cFbα and -cH2A
antibodies provides the best classifier to predict NI-0101
response (data not shown). Although ACPA alone has
not been demonstrated to be TLR4 ligands, ACPA forms
immune complexes containing antigens with innate
immunostimulatory capacity (i.e., cFb and citrullinated
histones), which have recently been reported to be a
TLR4 ligand [7, 43–45]. The presence of cFb-IC,
cHistones-IC and other TLR4-activating immune com-
plexes containing ACPA in the RASF samples may
explain the association between ACPA positivity in those
samples and their response to TLR4 blockade. In
support of the notion that cFb-IC have a role in TLR4-
driven joint inflammation, we observed that the profiling
of ACPA-positive RASF and paired serum samples from
patients with RA, by their reactivity to cFbα and cFbβ
chains, identified the TLR4-dependent subgroup with a
greater specificity than ACPA alone. Similarly, histones
are reported to enhance LPS-induced cytokine produc-
tion, further strengthening the central role of TLR4.
Also, more recently, citrullination of H2A and H2B were
demonstrated to enhance their capacity to stimulate pro-
inflammatory cytokine production [43, 46]. Therefore,
the presence of anti-cH2A antibodies in NI-0101 re-
sponder RASF may reflect the presence of a synergistic
effect of cH2A or ACPA complexed to cH2A with other
TLR4 ligands on TLR4-driven cytokine production. Fur-
thermore, when NI-0101 non-responder and partial re-
sponder RASF samples (defined by inhibition of IL-6
induction <50 %) are grouped together and compared to
the NI-0101 responder group (defined by inhibition of
IL-6 induction >50 %), the levels of two of the three
anti-cit peptide antibodies (i.e., cFbα-pept and cFbβ-pept)
are significantly lower in the non-responder and partial-
responder group (data not shown). These results suggest
that a partial response to NI-0101 may be associated with
the presence of ligands to other TLRs. Our data shed new
light on the role of ACPA reactivity, which may allow us
to identify ACPA-positive RASF with respect to ability to
mediate TLR4-driven cytokine production.
cFb-IC and cH2A-IC stimulate macrophage activation
through a mechanism involving both TLR4 and FcγRs
[7, 43]. The co-engagement of TLR4 and FcγRs may
increase the avidity of cFb-IC binding to the cell surface
and enhance its capacity to activate TLR4. Interestingly,
the NI-0101 mechanism of action involves the co-
engagement of TLR4 and FcγRs to increase its own
binding avidity and inhibitory capacity [17]. This mech-
anism of action is therefore well-fitted to block cFb-IC
and other immune-complex-induced TLR4 activation,
as it not only inhibits TLR4 signaling by blocking
receptor dimerization, but also has the potential to re-
duce the binding avidity of cFb-IC to the cell surface by
Table 1 The sensitivity and specificity of individual citrullinated peptides and their combinations in predicting NI-0101 response
ACPA-positive RASF ACPA-negative and ACPA-positive RASF
ACPA-related biomarkers Sensitivity Specificity Sensitivity Specificity
ACPA (CCP2) N/A N/A 85 % 75 %
cFbα-peptide (#1) 94 % 80 % 85 % 95 %
cFbβ-peptide (#2) 65 % 100 % 55 % 100 %
cH2A-peptide (#3) 70 % 80 % 60 % 95 %
(#1) + (#2) 94 % 80 % 85 % 95 %
(#1) + (#3) 100 % 80 % 90 % 95 %
(#2) + (#3) 88 % 80 % 75 % 95 %
(#1) + (#2) + (#3) 100 % 80 % 90 % 95 %
Sensitivity in this context is defined as the percentage of NI-0101 responders identified as positive in the assay and specificity as the percentage of NI-0101
non-responders identified as negative in the assay. Sensitivity and specificity were determined in the following groups: (i) anti-citrullinated protein antibodies
(ACPA)-positive rheumatoid arthritis synovial fluid (RASF) samples (n = 22), (ii) ACPA-negative and ACPA-positive RASF samples (n = 40). N/A not applicable,
CCP2 anti-cyclic citrullinated peptide-2
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competing for FcγR binding. Indeed, we demonstrated
that the Fc-dependent mechanism of action rendered
NI-0101 a more effective antibody in inhibiting cFb-IC-
stimulated TNF-α production from macrophages (see
Additional file 11). Similar data were generated using
H2B-IC stimulated macrophages (data not shown). The
mechanism of action of cFb-IC also suggests that it is
more effective in activating TLR4 on FcγR-bearing cells
than on FcγR-negative cells.
Taken together, this study demonstrates in vitro the
contribution of TLR4 to the inflammatory process in
specific subgroups of patients with RA, and that TLR4-
induced cytokine production can be blocked by a novel
therapeutic anti-human TLR4 antibody, NI-0101. The
results highlight TLR4 as a potential new therapeutic
target in RA and portend the use of TLR4 ligands and
ACPA fine profiles as biomarkers to predict the response
of individual patients with RA to TLR4 inhibitors. If
confirmed in clinical settings, ACPA specificities would
define a subpopulation of patients with RA, character-
ized with TLR4-mediated disease.
Conclusions
In summary, the data presented herein demonstrate
TLR4-dependent proinflammatory cytokine production
in samples from patients with RA, and its correlation
with the levels of TLR4 ligands in RASF and paired
serum samples. In particular, we showed that immune
complexes containing a subset of ACPA bound to their
specific autoantigens can activate cells via TLR4 and the
presence of these specific ACPA in patient RASF and
paired samples of sera predicts cellular response to
anti-TLR4 exposure in vitro. Furthermore, this study
suggests that ACPA fine profiling in blood could be
used as biomarkers to identify patients with RA who
could benefit from TLR4-targeted therapy. These find-
ings have been the foundation to design the proof-of-
concept clinical trial in ACPA-positive patients with
RA, aimed at validating the therapeutic potential of a
new first-in-class anti-TLR4 monoclonal antibody, NI-
0101, and the potential of predictive biomarkers (i.e.,
TLR4 ligands and in particular, levels of ACPA sub-
types in serum) to identify patients more likely to bene-
fit from TLR4 blockade by NI-0101. The clinical study
has recently been approved by the Food and Drug
Agency (FDA) and Medicines and Healthcare Products
Regulatory Agency (MHRA).
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Additional file 9: Receiver operating characteristic (ROC) curve analyses
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Fig. 5 Anti-citrullinated protein antibodies (ACPA) fine specificity in paired sera samples of patients with rheumatoid arthritis (RA) and their
correlation with RA synovial fluid (RASF) response to NI-0101. a Correlation between ACPA in paired samples of sera from patients with RA and
synovial fluids (n = 22). b ACPA in paired samples of sera from patients with RA classified according to RASF response to NI-0101 (NI-0101 non-
responders (NR) or NI-0101 responders (R)). c, d Antibody reactivity against the citrullinated peptides derived from fibrinogen-α (cFbα-pept),
fibrinogen-β (cFbβ-pept) and histone-2A (cH2A-pept) were determined by ELISA in paired samples of sera from patients with RA and correlation
with response to NI-0101 was tested. c Paired sera samples from ACPA-positive patients with RA (n = 13). d Paired samples of sera from
from ACPA-positive and ACPA-negative patients with RA (n = 22). The Mann-Whitney U test was performed to compare observed changes;
**p < 0.01, *p < 0.05
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